No Data
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Express News | Ascendis Pharma A/S : Citigroup Cuts Target Price to $200 From $207
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $153 to $207
Express News | Acendis Pharma Shares Are Trading Higher After Stifel Maintained a Buy Rating on the Stock and Raised Its Price Target From $200 to $207
European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week
No Data
No Data
factors that put the rise on are not from a rebound but from news, either way the price is above the price before financial reporting
